Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AARP Engages In Medicare Rx Debate; Focus Shifts To Senate

Executive Summary

AARP is concerned about the use of actuarial equivalence in the House Medicare Rx drug bill.

You may also be interested in...



Drug Firms Support Democratic Challenger For Congress In FDA Home District

Several large pharmaceutical manufacturers are supporting Democratic challenger Terry Lierman in his race against Republican incumbent Rep. Morella to represent the Maryland district that is home to FDA.

Drug Firms Support Democratic Challenger For Congress In FDA Home District

Several large pharmaceutical manufacturers are supporting Democratic challenger Terry Lierman in his race against Republican incumbent Rep. Morella to represent the Maryland district that is home to FDA.

Medicare Rx Disease Management Pilot Project Estimated To Cost $300 Mil.

A disease management program pilot project included in the House Medicare drug benefit bill (HR 4680) may have difficulty attracting private sector contractors, a Congressional Budget Office analysis of the bill indicates.

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel